10-Q: Tevogen Bio Holdings Inc. Reports First Quarter 2025 Financial Results

Tevogen Bio Holdings Inc. reports a net loss of $10.4 million for the first quarter of 2025, primarily due to operating expenses and non-cash stock-based compensation.

Summary

• Tevogen Bio Holdings Inc., a clinical-stage immunotherapy company, announced its financial results for the first quarter ended March 31, 2025.
• The company reported a net loss of $10.4 million, compared to a net income of $11.3 million for the same period in 2024.
• Research and development expenses were $3.2 million, a decrease from $20.8 million in the prior year, primarily due to stock-based compensation expense recognized as part of a business combination.
• General and administrative expenses were $7.2 million, compared to $8.7 million in the prior year.
• As of March 31, 2025, Tevogen Bio had cash of $2.0 million.
• The company believes its cash balance, amounts available under a loan agreement, and committed grant funding will be sufficient to fund operations for at least the next 12 months.
• Tevogen Bio is focused on developing off-the-shelf, precision T cell therapies for infectious diseases, cancers, and other disorders using its ExacTcell technology.
• The company's lead product candidate, TVGN 489, is being developed for the treatment of COVID-19 and Long COVID.
• A Phase 1 proof-of-concept clinical trial of TVGN 489 has been completed.
• The company is also exploring the use of artificial intelligence to accelerate drug development through its Tevogen.AI initiative.
• The company has drawn $3.0 million under the Loan Agreement as of March 31, 2025, and an additional $0.5 million in April 2025, leaving $25.0 million available.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company has made progress in its clinical trials and secured funding, it is still operating at a loss and has an accumulated deficit. The reliance on related-party funding also raises concerns.

Positives

• Tevogen Bio completed a Phase 1 clinical trial for TVGN 489 with positive results, showing a rapid reduction of viral load and no prevention of the development of the patients' own T cell-related or antibody-related anti-COVID-19 immunity.
• The company has secured a loan agreement providing access to up to $36.0 million in funding.
• KRHP has committed to providing an additional $8.0 million in grant funding.
• The company believes it has sufficient cash to fund operations for at least the next 12 months.
• The company is exploring the use of artificial intelligence to accelerate drug development through its Tevogen.AI initiative.

Negatives

• Tevogen Bio reported a net loss of $10.4 million for Q1 2025.
• The company has an accumulated deficit of $123.8 million as of March 31, 2025.
• The company has not generated any revenue to date.
• The company is in default of its obligations at March 31, 2025, as the outstanding balance of the notes payable was required to be repaid in full within five business days of the Merger.

Risks

• The company's research and development projects may not be successful.
• Products developed may not obtain necessary regulatory approval.
• Any approved product may not be commercially viable.
• The company operates in an environment of rapid technological change.
• The company is largely dependent on the services of its employees and consultants.
• The company may not be able to obtain financing on acceptable terms.
• The company may not be able to enter into strategic alliances or other arrangements on favorable terms.
• The terms of any financing may adversely affect the holdings or the rights of the company's stockholders.
• If the company is unable to obtain sufficient funding, the company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect its business prospects.
• The company is in default of its obligations at March 31, 2025, as the outstanding balance of the notes payable was required to be repaid in full within five business days of the Merger.

Future Outlook

Tevogen Bio believes its current cash balance, amounts available under the Loan Agreement, and committed grant funding will be sufficient to fund operations for at least the next 12 months. The company plans to continue developing its product candidates and exploring strategic opportunities.

Industry Context

Tevogen Bio operates in the competitive biotechnology industry, focusing on developing novel T cell therapies. The company's ExacTcell technology and focus on off-the-shelf, precision T cell therapies position it to potentially address unmet needs in infectious diseases, cancers, and other disorders.

Comparison to Industry Standards

• It is difficult to compare Tevogen Bio's results directly to industry standards due to its early stage and lack of revenue.
• Comparable companies in the clinical-stage immunotherapy space include companies such as Adaptimmune Therapeutics and Atara Biotherapeutics, which are also focused on developing T cell therapies.
• These companies often have high research and development expenses and may not be profitable until their products are approved and commercialized.
• Tevogen Bio's reliance on related-party funding through the Patel Family is a notable difference from many other publicly traded biotech companies, which typically rely more heavily on venture capital, public equity markets, and partnerships with larger pharmaceutical companies.

Related Party Transactions

• The company has a loan agreement with The Patel Family, LLP, a related party.
• The company issued Series A Preferred Stock and Series C Preferred Stock to the Patel Family.
• The company received a grant from KRHP LLC, which is affiliated with the Patel Family.
• The company contracted with Dr. Manmohan Patel of The Patel Family LLP to provide advisory services.
• The company entered into a Master Services and Facilities Agreement (the MSFA) with CD 8 Technology Services LLC (CD8), which is associated with Dr. Manmohan Patel.

Stakeholder Impact

• Shareholders: The company's financial performance and progress in clinical trials will impact shareholder value.
• Employees: The company's ability to secure funding and advance its programs will impact job security and opportunities.
• Patients: The success of the company's product candidates will impact the availability of new treatments for infectious diseases, cancers, and other disorders.
• Creditors: The company's ability to repay its debts will depend on its financial performance and ability to raise capital.

Next Steps

• Continue planned clinical trials of TVGN 489 and other product candidates.
• Advance pre-clinical studies and clinical trials of TVGN 489 for additional combinations, targets, and indications.
• Scale up manufacturing processes and capabilities to support clinical trials.
• Prepare regulatory filings for product candidates.
• Evaluate different strategies to obtain funding for operations for subsequent periods.

Key Dates

Keywords

Tevogen Bio, TVGN 489, ExacTcell, COVID-19, Immunotherapy, Clinical-stage, Financial results, Research and development, Loan agreement, KRHP, T cell therapies